Data To Be Presented on Gamida Cell Natural Killer Cell Therapy Candidate GDA-201 at the International Society for Cell Gene Therapy 2023 Annual Meeting
GMDADelisted Stock | USD 1.40 0.09 6.04% |
About 61% of Gamida Cell's investor base is looking to short. The analysis of current outlook of investing in Gamida Cell suggests that many traders are alarmed regarding Gamida Cell's prospects. The current market sentiment, together with Gamida Cell's historical and current headlines, can help investors time the market. In addition, many technical investors use Gamida Cell stock news signals to limit their universe of possible portfolio assets.
Gamida |
BOSTON, May 31, 2023 Gamida Cell Ltd. , a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that an oral presentation highlighting Gamida Cells investigational natural killer cell therapy candidate GDA-201 will be shared at the International Society for Cell and Gene Therapy 2023 Annual Meeting. The meeting takes place May 31-June 3 in Paris, France.
Read at finance.yahoo.com
Gamida Cell Fundamental Analysis
We analyze Gamida Cell's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Gamida Cell using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Gamida Cell based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Equity
Return On Equity Comparative Analysis
Gamida Cell is currently under evaluation in return on equity category among its peers. Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Gamida Cell Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Gamida Cell stock to make a market-neutral strategy. Peer analysis of Gamida Cell could also be used in its relative valuation, which is a method of valuing Gamida Cell by comparing valuation metrics with similar companies.
Peers
Gamida Cell Related Equities
XFOR | X4 Pharmaceuticals | 11.43 | ||||
TERN | Terns Pharmaceuticals | 7.82 | ||||
HOOK | Hookipa Pharma | 6.90 | ||||
ARDX | Ardelyx | 6.36 | ||||
MCRB | Seres Therapeutics | 4.55 | ||||
BLRX | BioLineRx | 3.57 | ||||
IOVA | Iovance Biotherapeutics | 3.07 | ||||
INZY | Inozyme Pharma | 2.64 | ||||
DAWN | Day One | 1.33 | ||||
PLX | Protalix Biotherapeutics | 0.60 | ||||
IBRX | Immunitybio | 0.39 | ||||
LXRX | Lexicon Pharmaceuticals | 2.44 |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Other Consideration for investing in Gamida Stock
If you are still planning to invest in Gamida Cell check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Gamida Cell's history and understand the potential risks before investing.
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |